ANXA2
ATC code L01
Abagovomab
Abemaciclib
Abituzumab
Acalabrutinib
Acute myelogenous leukemia
Acute myeloid leukemia
Adagrasib
Adecatumumab
Adipotide
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Antibody-drug conjugate
Antigen
Antineoplastic
Asciminib
Ascrinvacumab
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
BRAF (gene)
Balstilimab
Baricitinib
Bavituximab
Bcr-abl fusion protein
Bectumomab
Belantamab mafodotin
Bermekimab
Bevacizumab
Binimetinib
Biopharmaceutical
Bivatuzumab mertansine
Blinatumomab
Bone marrow transplantation
Bosutinib
Botensilimab
Boxed warning
Brentuximab vedotin
Brigatinib
Brontictuzumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Calicheamicin
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carotuximab
Catumaxomab
Cediranib
Celltech
Cemiplimab
Ceritinib
Cetuximab
ChEMBL
ChemSpider
Chimeric antibody
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
ClinicalTrials.gov
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Conatumumab
Copanlisib
Cosibelimab
Crizotinib
Dabrafenib
Dacetuzumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Daratumumab
Dasatinib
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Detumomab
Dinutuximab
Dinutuximab beta
Doi (identifier)
Dostarlimab
Doxorubicin
Drozitumab
DrugBank
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
EML4
Ecromeximab
Edrecolomab
Elotuzumab
Elranatamab
Emactuzumab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
Ertumaxomab
Etaracizumab
European Medicines Agency
Everolimus
Exotoxin
FDA
FDA Accelerated Approval Program
Farletuzumab
Fedratinib
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
Flanvotumab
Flotetuzumab
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Futuximab
Ganitumab
Gefitinib
Gemtuzumab ozogamicin (data page)
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glofitamab
HER2/neu
Hedgehog signaling pathway
Humanized
Humanized antibody
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Inavolisib
Indatuximab ravtansine
Indicated
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Infigratinib
Inotuzumab ozogamicin
Interleukin 2
Intetumumab
Intravenous therapy
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Istiratumab
Janus kinase
KEGG
KRAS
Labetuzumab
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Lexatumumab
Lifastuzumab vedotin
Lilotomab
Lintuzumab
List of withdrawn drugs
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lumretuzumab
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Mapatumumab
Margetuximab
Masitinib
Matuzumab
MedlinePlus
Midostaurin
Milatuzumab
Minretumomab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Mosunetuzumab
Mouse
Moxetumomab pasudotox
Myeloid
Nacolomab tafenatox
Naptumomab estafenatox
Narnatumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nesvacumab
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Ocaratuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Onartuzumab
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otlertuzumab
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Parsatuzumab
Patritumab
Pazopanib
Pembrolizumab
Pemigatinib
Pemtumomab
Pertuzumab
Pexidartinib
Pfizer
Phases of clinical research
Pi3K inhibitor
Pinatuzumab vedotin
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Pritumumab
Proapoptotic
Prohibitin
Prolgolimab
Public domain
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radotinib
Radretumab
Ramucirumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Response rate (medicine)
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Rituximab
Robatumumab
Rociletinib
Rosmantuzumab
Route of administration
Rovalpituzumab tesirine
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Selpercatinib
Selumetinib
Semaxanib
Seribantumab
Serplulimab
Sibrotuzumab
Siltuximab
Simtuzumab
Sirolimus
Sofituzumab vedotin
Solitomab
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Standard for the Uniform Scheduling of Medicines and Poisons
Stem cells
Sugemalimab
Sunitinib
Surrogate endpoint
Tafasitamab
Talquetamab
Taplitumomab paptox
Tarextumab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Technetium (99mTc) arcitumomab
Technetium (99mTc) nofetumomab merpentan
Technetium (99mTc) pintumomab
Technetium (99mTc) votumumab
Teclistamab
Temsirolimus
Tenatumomab
Tepotinib
Teprotumumab
The New York Times
Therapeutic Goods Administration
Tigatuzumab
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Toripalimab
Tositumomab
Tovetumab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trifunctional antibody
Trilaciclib
Tucatinib
Tucotuzumab celmoleukin
Tyrosine kinase inhibitor
UCB (company)
Ublituximab
Unique Ingredient Identifier
VEGF receptors
Vandetanib
Vandortuzumab vedotin
Vantictumab
Vanucizumab
Vascular endothelial growth factor
Vascular endothelial growth factor A
Veltuzumab
Vemurafenib
Venetoclax
Veno-occlusive disease
Vismodegib
Vorsetuzumab mafodotin
WHO Model List of Essential Medicines
Wyeth
Yttrium (90Y) clivatuzumab tetraxetan
Yttrium (90Y) tacatuzumab tetraxetan
Zalutumumab
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab